Despite olaparib and ATR inhibitors demonstrating various degrees of monotherapy efficacy in ATM-deficient cancers [13–15, 27–29, 60, 61], our work highlights the importance of exploring their use in combination through the potential to optimise lower doses and shorter treatment periods due to synergistic activity. This evidence concerns the gene ATM and cancer.